

Name: Timo Tapio Myöhänen
Orcid ID: orcid.org/0000-0002-9277-6687

1. Original research articles

1. **Myöhänen TT**, Venäläinen JI, Tupala E, Garcia-Horsman JA, Miettinen R, Männistö PT: Distribution of immunoreactive prolyl oligopeptidase in the rat brain. *Neurochemical Research* 32:1365-1374, 2007
2. **Myöhänen TT**, Venäläinen JI, Garcia-Horsman JA, Piltonen M, Männistö PT: Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. *Journal of Comparative Neurology* 507: 1694-1708, 2008
3. **Myöhänen TT**, Venäläinen JI, Garcia-Horsman JA, Männistö PT: Spatial association of prolyl oligopeptidase, inositol 1,4,5-triphosphate type 1 receptor, substance P and its NK-1 receptor in the rat brain: An immunohistochemical study. *Neuroscience* 153: 1177-1189, 2008
4. **Myöhänen TT**, Venäläinen JI, Garcia-Horsman JA, Piltonen M, Männistö PT: Distribution of prolyl oligopeptidase in mouse whole-body and peripheral tissues. *Histochemistry and Cell Biology* 130: 993-1003, 2008
5. **Myöhänen TT**, Kääriäinen TM, Jalkanen AJ, Piltonen M, Männistö PT: Prolyl oligopeptidase in the reciprocal connections between thalamus and cortex: A retrograde neurotracing study. *Neuroscience Letters* 450: 201-205, 2009
6. Käenmäki M, Tammimäki A, Garcia-Horsman JA, **Myöhänen TT**, Schendzielorz N, Karayiorgou M, Gogos J, Männistö PT: Importance of the two forms of catechol-O-methyltransferase (COMT) in L-dopa metabolism: a pharmacokinetic study in two types of *Comt* gene modified mice. *British Journal of Pharmacology* 158: 1884-1894, 2009
7. **Myöhänen TT**, Schendzielorz N, Männistö PT: Distribution of immunoreactive catechol-O-methyltransferase (COMT) and its enzyme activities in wild-type and soluble-COMT deficient mouse. *Journal of Neurochemistry* 113: 1632-1643, 2010
8. Käenmäki M, Tammimäki A, **Myöhänen TT**, Pakarinen K, Amberg C, Karayiorgou M, Gogos J, Männistö PT: Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. *Journal of Neurochemistry* 114: 1745-55, 2010.
9. Peltonen I, **Myöhänen TT**, Männistö PT: Association of prolyl oligopeptidase and conventional neurotransmitters in the brain. *CNS & Neurological Disorders – Drug Targets* 10: 311-318, 2011
10. Hannula M, Männistö PT, **Myöhänen TT**: Sequential expression, activity and nuclear localization of prolyl oligopeptidase in the developing rat brain. *Developmental Neuroscience* 33: 38-47, 2011

11. **Myöhänen TT**, Tenorio-Laranga J, Jokinen B, Moreno-Baylach MJ, Vasques R, Garcia-Horsman JA, Männistö PT: Prolyl oligopeptidase (POP) induces angiogenesis both *in vitro* and *in vivo* in a novel regulatory manner. *British Journal of Pharmacology* 163: 1666-78, 2011. doi: 10.1111/j.1476-5381.2010.01146.x.
12. Piltonen M, Planken A, Leskelä O, **Myöhänen TT**, Hänninen AL, Auvinen P, Alitalo K, Andressoo JO, Saarma M, Männistö PT: Vascular endothelial growth factor C (VEGF-C) acts as a neurotrophic factor for dopamine neurons *in vitro* and *in vivo*. *Neuroscience* 192: 550-563, 2011
13. **Myöhänen TT**, Hannula MJ, Van Elzen R, Gerard M, Van Der Veken P, Baekelandt V, Garcia-Horsman JA, Männistö PT, Lambeir AM: The prolyl oligopeptidase inhibitor, KYP-2047, reduces α -synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. *British Journal of Pharmacology*, 166: 1097-113, 2012. doi: 10.1111/j.1476-5381.2012.01846.x.
14. Peltonen I, **Myöhänen TT**, Männistö PT: Interaction of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways. *Neurochemical Research* 37:2033-2041, 2012
15. **Myöhänen TT**, Pyykkö E, Männistö PT, Carpen O: The distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors. *Journal of Histochemistry and Cytochemistry* 60: 706-715, 2012
16. Piltonen M, Savolainen MH, Patrikainen S, Baekelandt V, **Myöhänen TT**, Männistö PT: Comparison of motor performance, brain biochemistry and histology of two mouse lines carrying different α -synuclein mutations. *Neuroscience* 231: 157-168, 2013
17. Schendzielorz N, Oinas J-P, **Myöhänen TT**, Reenilä I, Raasmaja A, Männistö PT: Catechol-*O*-methyltransferase (COMT) protein expression and activity after dopaminergic and noradrenergic lesions of the rat brain. *Plos One* 8:e61392, 2013
18. Hannula MJ, **Myöhänen TT**, Tenorio-Laranga J, Männistö PT, Garcia-Horsman JA: Prolyl oligopeptidase colocalizes with α -synuclein, β -amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases. *Neuroscience* 242:140-150, 2013
19. Y, Chun B, Potthoff SA, Kazi N, Brolin TJ, Orhan D, Yang HC, Kon V, **Myöhänen TT**, Rhaleb NE, Carratero OA, Kleinman HK, Fogo AB: Thymosin β 4 and Ac-SDKP, Novel Reparative Factors in Renal Fibrosis. *Kidney International* 84:1166-1175, 2013
20. Savolainen MH, Richie C, Harvey BK, Männistö PT, Maguire-Zeiss KA, **Myöhänen TT**: The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse. *Neurobiology of disease* 68C:1-15, 2014
21. Vihko P, Nousiainen HO, **Myöhänen TT**, Voikar V, Quintero I, Mijatovic J, Segerstråle M, Herrala AK, Kuleskaya N, Pulkka A, Kivinummi T, Ramadan UA, Taira T, Piepponen TP, Rauvala H: Mice deficient of Prostatic Acid Phosphatase displays multiple hallmarks of schizophrenia. *PlosOne* 9(5):e97851, 2014

22. Kim JD, Toda C, Liu ZW, D'Agostino G, Zeiss C, DiLeone R, Kibbey RG, Chan O, Harvey BK, Richie C, Savolainen MH, **Myöhänen T**, Jeong JK, Diano S: Hypothalamic Prolyl Endopeptidase (PREP) regulates pancreatic insulin and glucagon secretion in mice. *PNAS* 111:11876-11881, 2014
23. Ahonen L, Maire F, Savolainen M, Kopra J, Vreeken RJ, Hankemeier T, **Myöhänen TT**, Kylli P, Kostianen R: Analysis of oxysterols and vitamin D metabolites in mouse brain and cell line samples by ultra performance liquid chromatography-atmospheric pressure photoionization-mass spectrometry. *Journal of Chromatography A* 1364:214-22, 2014
24. Dokleja L, Hannula MH, **Myöhänen TT**: Prolyl oligopeptidase inhibition attenuates the effect of rotenone on α -synuclein aggregation and cell death on α -synuclein overexpressing cells. *Neuroscience Letters* 538C:37-42, 2014
25. Savolainen MH, Yan X, **Myöhänen TT**, Huttunen H.: Prolyl oligopeptidase enhances α -synuclein dimerization via direct protein-protein interaction. *Journal of Biological Chemistry* 290: 5117-5126, 2015
26. Svarcbahs R, Julku UH, **Myöhänen TT**: Inhibition of Prolyl Oligopeptidase restores spontaneous motor behavior in alpha-synuclein virus vector based Parkinson's disease mouse model by decreasing alpha-synuclein oligomeric species in mouse brain. *Journal of Neuroscience* 36: 12485-12497, 2016
27. **Myöhänen TT**, Norrbacka S, Savolainen MH: Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture. *Neuroscience Letters* 636: 83-89, 2017
28. Savolainen MH, Albert K, Airavaara M, **Myöhänen TT**: Nigral injection of a proteasomal inhibitor, lactacystin, induces wide-spread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse. *Experimental Brain Research* 235: 2189-2202, 2017
29. Svarcbahs R, Julku UH, Norrbacka S, **Myöhänen TT**: Removal of Prolyl Oligopeptidase Attenuates the Toxicity of Alpha-Synuclein in Cells and In Vivo. *Scientific Reports* 8: 1552, 2018
30. Kopra J, Villarta-Aguilera M, Savolainen M, **Myöhänen TT**, Rannanpää S, Salvatore MF, Saarma M, Anderssoo JO, Piepponen P: Constitutive Ret signalling leads to longer expression of amphetamine-induced place conditioning via elevation of mesolimbic dopamine. *Neuropharmacology* 128: 221-230, 2018
31. Julku UH, Panhelainen A, Tiilkainen S, Svarcbahs R, Tammimäki A, Piepponen TP, Savolainen MH, **Myöhänen TT**: Prolyl oligopeptidase regulates dopamine transporters in nigrostriatal tract in mice. *Molecular Neurobiology* 55: 470-482, 2018
32. Norrbacka S, Lindholm D, **Myöhänen TT**: Prolyl oligopeptidase inhibition attenuates lactacystin toxicity in cellular model of Huntington's disease. *Journal of Cellular and Molecular Medicine* 23: 8511-8515, 2019

33. Kilpeläinen T, Julku U, Svarcbaht R, **Myöhänen TT**: Re-characterization of Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson's disease. *Scientific Reports* 9: 1738, 2019
34. Kilpeläinen T, Tyni JK, Lahtela-Kakkonen MK, Eteläinen T, **Myöhänen TT**, Wallen EAA: The effect of 4-phenylbutanoyl-aminoacyl-2(S)-tetrazolylpyrrolidines on the functions of prolyl oligopeptidase. *ACS Medicinal Chemical Letters* 10: 1635-1640, 2019
35. Serfozo P, Wysocki J, Gulua G, Ye M, Liu P, Jin J, Bader M, **Myöhänen T**, García-Horsman JA, Battle D: Angiotensin II Conversion to Angiotensin (1-7) in the circulation is Prolyl Endopeptidase-Dependent and Angiotensin Converting Enzyme 2-Independent. *Hypertension* 75:173-182, 2020
36. Svarcbaht R, Jäntti M, Kilpeläinen T, Julku U, Urvas L, Kivioja S, Norrbacka S, **Myöhänen TT**: Prolyl oligopeptidase inhibition activates protein phosphatase 2A. *Pharmacological Research* 151: 104558., 2020
37. Kilpeläinen T, Hellinen L, Vrijdag J, Yan X, Svarcbaht R, Vellonen KS, Lambeir AM, Huttunen H, Urtti A, Wallen EAA, **Myöhänen TT**: The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy. *Biomedicine & Pharmacotherapy* 128: 110253, 2020
38. Rostami J, Jäntti M, Cui H, Rinne MK, Kukkonen JP, Falk A, Erlandsson A, **Myöhänen T**. Prolyl oligopeptidase inhibition by KYP-2047 increases alpha-synuclein fibril degradation in neuron-like cells. *Biomedicine & Pharmacotherapy* 133:111019, 2021
39. Julku U, Jäntti M, Svarcbaht R, **Myöhänen TT**: Prolyl oligopeptidase regulates dopamine transporter phosphorylation by PKC and ERK independent manner. *International Journal of Molecular Sciences* 22:1777, 2021
40. Klionsky DJ...**Myöhänen TT**... Zhuang X, Zong WX: Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (4th edition). *Autophagy* 17:1-382, 2021
41. Eteläinen T, Kulmala V, Jäntti M, **Myöhänen TT**: Prolyl Oligopeptidase Inhibition Reduces Oxidative Stress via Reducing NADPH Oxidase Activity by Activating Protein Phosphatase 2A. *Free Radical Biology & Medicine* 169:14-23, 2021
42. **Myöhänen TT**, Merten F, Norrbacka S, Cui H: Deletion or inhibition of prolyl oligopeptidase blocks molecular effects of lithium by activation of protein phosphatase 2A. *Basic & Clinical Pharmacology & Toxicology* 29:287-296, 2021
43. Cui H, Kilpeläinen T, Zouzoula L, Auno S, Trontti K, Kurvonen S, Norrbacka S, Hovatta I, Jensen PH, **Myöhänen TT**: Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy. *Journal of Cellular and Molecular Medicine*. doi: 10.1111/jcmm.16910, 2021
44. Heininen J, Vaikkinen A, Julku U, **Myöhänen TT**, Kotiaho T, Kostianen R: Quantitative multiplexed analysis of amino acids in mice brain microdialysis samples using isobaric labelling and liquid chromatography-high resolution tandem mass spectrometry. *Journal of Chromatography A*. doi.org: 10.1016/j.chroma.2021.462537, 2021

45. Pätsi H, Kilpeläinen T, Auno, S, Dillemath P, Arja K, Lahtela-Kakkonen M, **Myöhänen TT**, Wallén E: Imidazole as a substitute for the electrophilic group gives highly potent prolyl oligopeptidase inhibitors with a new putative binding mode. *ACS Medicinal Chemistry Letters*. DOI: 10.1021/acsmchemlett.1c00399, 2021

Peer-reviewed review articles in international journals

46. **Myöhänen TT**, Garcia-Horsman JA, Tenorio-Laranga J, Männistö PT: Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. *Journal of Histochemistry and Cytochemistry* 57: 831-849, 2009. *Review*.
47. **Myöhänen TT** & Männistö PT: Distribution and functions of COMT proteins: do recent findings change the picture (Chapter 3). *International Reviews of Neurobiology* 95: 29-47, 2010. *Review*.
48. Svarebaks R, Julku UH, Kilpeläinen T, Kyyrö M, Jäntti M, **Myöhänen TT**: New tricks of prolyl oligopeptidase inhibitors -a common drug therapy for several neurodegenerative diseases. *Biochemical Pharmacology* 161:113-120, 2019. *Review*.

2. Peer-reviewed scientific articles in national journals

49. **Myöhänen TT**: Prolyylioligopeptidaasin estäjällä Parkinsonin tautia vastaan. *Duodecim* 133:89, 2017 (A journal of The Finnish Medical Society Duodecim, article in Finnish)
50. **Myöhänen TT** & Kursula P: Entsyymien merkitys hermoja rappaavissa sairauksissa. *Duodecim*, 135:745-52, 2019 (A journal of The Finnish Medical Society Duodecim, article in Finnish)